Pancreatic Cancer

2024-AACR- FOLFIRINOX with glycogen synthase kinase-3 beta (GSK-3β) inhibitor elraglusib and transforming growth factor-β (TGFβ) inhibitor losartan in untreated metastatic pancreatic ductal adenocarcinoma (PDAC): interim analysis of safety cohort

Presentations /

2024-AACR- FOLFIRINOX with glycogen synthase kinase-3 beta (GSK-3β) inhibitor elraglusib and transforming growth factor-β (TGFβ) inhibitor losartan in untreated metastatic pancreatic ductal adenocarcinoma (PDAC): interim analysis of safety cohort Read More »

2024-ASCO-Mutational analysis of cfDNA to identify predictive biomarkers in previously untreated patients with metastatic pancreatic cancer receiving the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study

Publications /

2024-ASCO-Mutational analysis of cfDNA to identify predictive biomarkers in previously untreated patients with metastatic pancreatic cancer receiving the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study Read More »

2024-ASCO-Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.

Publications /

2024-ASCO-Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. Read More »

2024-ASCO-Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.

Publications /

2024-ASCO-Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. Read More »

2023-ASCO-Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).

Publications /

2023-ASCO-Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC). Read More »